US Patent 11058705 Drug formulations
Patent 11058705 was granted and assigned to Astex Pharmaceuticals on July, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+374 characters)
Article
Patent abstract
The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Chunlin Tang0
Harish Ravivarapu0
Rajashree Joshi-Hangal0
Sanjeev Redkar0
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 3 Apr, 2023
Golden AI
Infobox
Edits on 22 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 28 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 12 Feb, 2022
Golden AI
Edits made to:
Infobox (+12 properties)
US Patent 11058705 Drug formulations
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11058705
Date of patent
July 13, 2021
Patent application number
16675785
Date Filed
November 6, 2019
Patent citations
Patent primary examiner
Find more entities like US Patent 11058705 Drug formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
